The CDK1/cyclinD6/4 and PI3K/AKT/mTOR pathways have become a desirable target for the treatment of many cancers, with resistant breast cancer being one of them, as tumorigenesis is largely dependent on uncontrolled cell cycle progression [37]. The gene discussed is MTOR; the disease is breast carcinoma.